Duchenne muscular dystrophy (DMD) is a degenerative disease primarily affecting voluntary muscles with secondary consequences on heart and breathing muscles. DMD is an X-linked recessive disease that results in the loss of dystrophin, a key muscle protein. Inflammation can play different roles in DMD; it can be a secondary response to muscle degeneration, a primary cause of degeneration, or can contribute to the disease progression. Several immunosuppressants have been used with the aim to reduce the inflammation associated with DMD. Most recently, myoblast transplantation has shown the possibility to restore the dystrophin lack in the DMD patient's muscle fibers and this evidence has emphasized the importance of the use of immunosuppressants and the necessity of studying them and their secondary effects. The aim of this review is to analyze the main immunosuppressants drugs starting from the mdx mice experiments and concluding with the most recent human clinical studies.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is characterized by a progressive loss of muscle function. Inflammatory pathways mediated by neutrophils, macrophages, and associated to cytokines have been suggested to have a possible role in the damage of dystrophic muscles. (Reactive oxygen species may be important in both the activation of and the damage caused by this inflammatory pathway in mdx muscle. 1 ) Gosselin et al reported that a persistent inflammatory response has been observed in dystrophic skeletal muscle leading to an alteration in extracellular environment, including an increased presence of inflammatory cells such as macrophages and elevated levels of various inflammatory cytokines such as tumor necrosis factor alpha (TNFa) and tumor necrosis factor beta. 2 Moreover, the proinflammatory cytokine TNF was shown to increase necrosis of skeletal muscle. Studies conducted on the DMD mdx mouse model support this fact reporting that the depletion of inflammatory cells such as neutrophils, cromolyn blockade of mast cell degranulation, or pharmacological blockade of TNF reduces necrosis of dystrophic myofibers. 3 Patients affected by DMD show problems climbing stairs, rising up from the floor, and are unable to run and in a variable way the most of them lose ambulation by 7 to 12 years. Other DMD complications are the progressive loss of respiratory function that can lead to respiratory failure, scoliosis, weight loss, cardiomyopathy, and finally death as a result of respiratory and cardiac complications. Unfortunately, there is no cure for this disease. Corticosteroids slow its progression, although their mechanism of action is not well known. Two corticosteroids, prednisone and deflazacort, have been used extensively because of their ability to improve skeletal muscle function. Recently, the interest on the suppressing drugs acting against TNF level and suppressing calcineurin signals has increased. Beyond the anti-inflammatory chemical compounds, growing interest either in mice or in humans was focused on immunosuppressant drugs that potentially might give clinical benefit during the DMD course. The interest in immunosuppressants is also growing
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The aim of this review is to revisit the main important DMD clinical trials starting from the experimental studies in mice.
MDX MICE AND IMMUNOSUPPRESSANTS
MD is caused by loss of expression of dystrophin, a protein of 427 kDa that links the cytoskeleton to a complex of proteins localized on the surface of the membrane of muscle fibers and is able to interact with the extracellular matrix. The literature evidences that the most commonly used DMD model is the mdx mouse because of his genetic mutation resulting in the loss of dystrophin.
CALCINEURIN INHIBITORS
Calcineurin (Fig. 1) is a serine/threonine phosphatase controlled by cellular calcium, initially identified in extracts of mammalian brain.
Neural recruitment results in sarcolemmal membrane depolarization followed by the increase in intracellular Ca ++ levels. It phosphoryles nuclear factor of activated T-cells (NFAT) that are important in the transcription of interleukin-2 genes.
This increase in intracellular Ca
Calcineurin and NFAT play an important role in the activation of Type I and IIA myosin cheavy chain (MHC), oxidative enzyme, and utrophin A genes; it also acts through myocyteenhancing factor 2-dependent transcription.
Calcineurin inhibitors are orally administered for the treatment of atopic dermatitis 4 and seborrheic dermatitis. 5 Calcineurin inhibition has been observed using cyclosporine A block activation of lymphocyte T, causing an immunosuppressant effect.
Parsons et al 6 showed that inhibition of calcineurin may benefit some types of muscular dystrophy. They examined the effect of altered calcineurin activation in a deltasarcoglycan-null (scgd (-/-) ) mouse model of limb-girdle muscular dystrophy (LGMD; delta sarcoglycan is a model of LGMD2F). The authors showed that genetic deletion of a loxPtargeted calcineurin B1 gene using a skeletal muscle-specific Cre allele in the scgd (-/-) background substantially reduced skeletal muscle degeneration and histopathology compared with the scgd (-/-) genotype alone.
A similar regression in scgd-dependent disease manifestation has also been observed in calcineurin A(beta) gene-targeted mice in both skeletal muscle and heart, whereas increased calcineurin expression, using a muscle-specific transgene, is able to promote the increase of cardiac fibrosis and the decrease of cardiac ventricular shortening. An increased calcineurin expression is also correlated with an increase of muscle fiber loss in the quadriceps.
Debio 025
In the last 2 years, several studies and experiments involving the use of mdx mice have been performed using a cyclophilin inhibitor named Debio 025 (C 63 H 113 N 11 O 12 ; Fig. 2 ). This drug, developed by the Debiopharma Groupä, (Lausanne, Switzerland) was first used as a treatment for hepatitis C. 7 Debio-025 is a synthetic cyclosporine without immunosuppressive properties but faster, showed alteration in the stimulation frequency-dependent recruitment of muscle fibers, and displayed a higher resistance to mechanical stress. The authors concluded that Debio 025 improved the structure and the function of the dystrophic mouse muscle, suggesting that therapies targeting the mPTP may be helpful to patients with DMD. In several muscular dystrophies, there is a compromise of the support network that connects myofilament proteins within the cell to the basal lamina outside the cell, making the sarcolemma more permeable or leaky. Millay et al 10 showed that the deletion of the gene encoding cyclophilin D (Ppif) is responsible for the mitochondria insensitivity to the calcium overload-induced swelling associated with a defective sarcolemma leading to the myofiber necrosis in two distinct models of muscular dystrophy. The authors evidenced that mice lacking delta-sarcoglycan (Scgd (-/-) mice) displayed markedly less dystrophic disease in both skeletal muscle and heart in the absence of Ppif. Moreover, the premature lethality associated with deletion of Lama2, encoding the alpha-2 chain of laminin-2, was rescued, as other indices of dystrophic disease were. Treatment with the cyclophilin inhibitor Debio-025 was able to reduce mitochondrial swelling and necrotic disease manifestations in mdx mice and in Scgd (-/-) mice. Based on the previously described evidence, the authors concluded that mitochondrial-dependent necrosis represents a prominent disease mechanism in muscular dystrophy, suggesting that inhibition of Ppif could provide a new pharmacologic treatment strategy for these diseases.
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Cyclosporine A CsA (C 62 H 111 N 11 O 12 ; Fig. 3 ) is a fungal metabolite derived by Tolypocladium inflatum. CsA was discovered in 1971 and has potent immunosuppressive properties. Cyclosporine inhibits calcineurin by binding to the protein and inhibiting its ability to dephosphorylate substrates such as NFATc family members, thus preventing their nuclear localization. This drug is able to prevent graft rejection inhibiting the T-cell receptor signal transduction pathway through the formation of the CsA2cyclophilin complex that inhibits calcineurin (protein phosphatase 2B). CsA also inhibits nitric oxide synthesis induced by interleukin 1a, lipopolysaccharides, and TNFa and can block cytochrome C release from mitochondria. Gonc xalves et al 11 evidenced some CsA important side effects such as liver and kidney damage, high blood pressure, hirsutism, nausea and emesis, and gingival overgrowth.
CsA use in organ transplantation was approved in 2001 to prevent graft rejection in kidney, liver, heart, lungs, and combined heart-lung transplants. CsA is able to prevent the rejection after bone marrow transplantation and during prophylaxis of host-versusgraft disease. CsA has also been widely and successfully used in allogeneic hematopoietic cell transplantation (HCT). Hogan et al 12 reported the use of CsA in several clinical trials involving human patients undergoing HCT. This drug is also used for the treatment of psoriasis, atopic dermatitis, rheumatoid arthritis, and nephrotic syndrome despite of its time-and dose-dependent toxicity against kidneys. This drug is also widely used in postallogeneic organ transplant to reduce the activity of the patient's immune system with risks of organ rejection.
CsA is metabolized into a vast spectrum of metabolites and exerts its immunosuppressive action by inhibiting the enzyme calcineurin phosphatase.
Marx et al 13 conducted a study to investigate possible additive effects of calcium antagonists on the CsA-induced inhibition of cellular immunity. Human T-cells were isolated using standard methods and stimulated with phytohemagglutinin (n = 8), the monoclonal antibody OKT3 (n = 6), or mixed lymphocyte reaction (n = 5 
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Pierno et al 18 evaluated the role of TNFa or cyclo-oxygenase-2 eicosanoids in dystrophinopathies.
The authors treated adult dystrophic mdx mice with the anti-TNFa etanercept (0.5 mg/kg) or the cyclo-oxygenase-2 inhibitor meloxicam (0.2 mg/kg) for 4 to 8 weeks.
Throughout the treatment period, the mdx mice underwent a protocol of exercise on a treadmill worsening the progression of pathology; gastrocnemius muscles from exercised mdx mice showed an intense staining for TNFa by immunohistochemistry. In vivo etanercept, but not meloxicam, improved the exercise-induced forelimb force drop. Electrophysiological recordings ex vivo showed that etanercept was able to counteract the decrease in chloride conductance, a functional index of myofiber damage, in both diaphragm and extensor digitorum longus muscle. Instead, meloxicam is effective only in extensor digitorum longus muscle. None of the drugs ameliorate calcium homeostasis detected by electrophysiology and/or spectrofluorimetry. Etanercept more than meloxicam reduced plasma creatine kinase (CK) and etanercept-treated muscles showed a reduction of connective tissue area and of profibrotic cytokine transforming growth factor-b1 versus untreated ones. The histology profile of gastrocnemious was significantly improved with a reduction of degenerating area and CK levels were only slightly lower. The previously described findings suggest that TNFa, but not cyclo-oxygenase-2, plays a key role in different phases of dystrophic progression and antiTNFa drugs can be used in combination therapies in DMD.
Hodgetts et al 19 tested, in dystrophindeficient mice, the hypothesis that the initial sarcolemmal breakdown resulting from dystrophin deficiency is exacerbated by inflammatory cells, specifically neutrophils, and that cytokines, specifically TNFa, is able to contribute to myofiber necrosis. Antibody depletion of host neutrophils resulted in a delayed and significantly reduced amount of skeletal muscle breakdown in young dystrophic mdx mice. A more striking and prolonged protective effect was seen after pharmacologic blockade of TNFa bioactivity using etanercept. The extent of exercise induced myofiber necrosis in adult mdx mice after voluntary wheel exercise was also reduced after etanercept administration. The previously reported data show a clear role for neutrophils and TNFa in necrosis of dystrophic mdx muscle in vivo. Etanercept is a highly specific anti-inflammatory drug, widely used clinically, and its potential application to muscular dystrophies is suggested by this reduced breakdown of mdx skeletal muscle. Etanercept caused the following side effects: redness, itching, pain, or swelling at the injection site; colds; cough; headache; and nausea. Fig. 6 ) is a chimeric monoclonal antibody targeted against TNFa and approved by the U.S. Food and Drug Administration in 1998 to treat children (age 6 years or older) and adults with Crohn disease who do not respond to traditional therapies. There is evidence that the overstimulation of TNFa is implicated in causing psoriasis and other autoimmune disorders because rheumatoid arthritis and infliximab can prevent TNFa from triggering inflammation in the body by blocking the activities of cell surface receptors.
Grounds et al 20 tested infliximab in young dystrophic mdx mice to confirm the FIGURE 6. Infliximab structure. 
Immunosuppressants in DMD
STEROID-BASED DRUGS Prednisone and Deflazacort
Glucocorticoids are routinely and effectively used to treat chronic inflammatory diseases. There is evidence in literature of their use both in mice and human clinical trials with beneficial effects in the treatment of DMD. The two main steroids used are prednisone (Fig. 7) and deflazacort (Fig. 8 ).
These are probably equally effective in stabilizing muscle strength but may have different side effect profiles (for instance, deflazacort causes less weight gain).
Prednisone is used in autoimmune diseases, severe asthma, severe allergies, rheumatoid arthritis, Bell's palsy, Crohn disease, pemphigus and sarcoidosis, uveitis, and other inflammatory disease.
It is also used in various kidney diseases such as nephrotic syndrome, mononucleosis, and to prevent and treat rejection in organ transplantation. Deflazacort (C 25 H 31 NO 6 ), an oxazoline derivative of prednisone (C 21 H 26 O 5 ), with high immunosuppressant capacity, is a synthetic glucocorticoid that has a crucial role in the treatment of patients with autoimmune disorders associated with central nervous system or metabolic manifestations.
Anderson et al 21 studied the effects of deflazacort and prednisone on muscle regeneration in mdx mice during a period of 4 to 5 weeks. They tested and compared these immunosuppressant drugs evaluating their power to decrease dystrophy through inflammatory effect suppression and increasing new muscle formation after crush injuries. Deflazacort but not prednisone increased the centronucleation index of accumulated damage and repair and myotube growth over the long term.
In crush-injured left tibialis anterior muscle, the fusion of proliferative muscle precursors to myotubes was increased only after deflazacort and the diaphragm muscle was much less inflamed, and fiber diameter was greater after deflazacort. The authors observed that only 
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CYTOSTATICS Azathioprine
Azathioprine (C 9 H 7 N 7 O 2 S; Fig. 9 ) is a purine synthesis inhibitor used in organ transplantation, rheumatoid arthritis, pemphigus, or Crohn disease and ulcerative colitis. It is able to inhibit the proliferation of cells, in particular leukocytes, but patients will be more susceptible to infections. 
OTHER IMMUNOSUPPRESSIVE DRUGS Mycophenolate Mofetil
Mycophenolate mofetil (MMF; CellCept, Roche, Switzerland; Fig. 10 ) is a salt form of the immunosuppressive drug mycophenolic acid. The salt form is much better tolerated and allows good and rapid absorption by the body before it is converted to the active agent, mycophenolic acid.
Mycophenolic acid is a selective inhibitor of inosine monophosphate dehydrogenase, thereby preventing the synthesis of guanosine nucleotide and resulting in cytostatic effect on T and B lymphocytes, inhibiting proliferation, and antibody production. It is used primarily in immunosuppressive regimens to prevent rejection of allogeneic cardiac, hepatic, and renal transplants.
More recently, it has been used to treat various nontransplant-related conditions, including autoimmune skin disorders: psoriasis, atopic dermatitis, sarcoidosis, cutaneous vasculitis, and lupus erythematosus.
MMF is available in both oral and intravenous preparations.
Strober et al 26 tested MMF in mdx mice.
Mdx mice were treated through intraperitoneal injection daily with 80 mg/kg MMF, 1 mg/kg prednisone, or vehicle. Injections were started on day of life 10 and mice were killed at 3, 4, and 5 weeks of age. The diaphragm, tibialis anterior, and quadriceps muscles were removed and the sections were evaluated by an observer blinded to treatment type for necrosis, central nuclei, and inflammatory infiltrate. This study brought the following results: the MMF group showed a significantly smaller percentage of central nuclei than the control group and the prednisone-treated group for the quadriceps at 4 weeks and the tibialis anterior at 4 and 5 weeks; MMF treatment inhibited muscle degeneration in mdx mice better than steroids; a trend toward improvement in necrosis and degeneration in the quadriceps and tibialis anteriors was seen but for greater significance, more samples have to be analyzed; MMF reduced the percentage of centrally located nuclei in the quadriceps and tibialis anterior muscles of mdx mice compared with mice treated with prednisone. The authors concluded that MMF, a drug with already excellent safety data in transplant patients, is a good candidate for treatment of DMD.
IMMUNOSUPPRESSANTS IN CLINICAL TRIALS
Here are summarized the most important human clinical trials in DMD we found in the literature involving the use of immunosuppressant drugs such as deflazacort azothiaprine prednisone, oxandrolone, tacrolimus, and CsA.
Biggar et al 27 compared the long-term effects of the deflazacort treatment using two treatment protocols from Naples (N) and Toronto (T). The study involved boys, aged between 8 and 15 years, with DMD who had 4 or more years of deflazacort treatment. Diagnostic criteria were proximal muscle weakness evident before 5 years and increased serum CK and genetic testing and/or a muscle biopsy consistent with DMD. Thirtyseven boys were treated with protocol-N using deflazacort at a dose of 0.6 mg/kg per day for the first 20 days of the month and no deflazacort for the remainder of the month. Boys with osteoporosis received daily vitamin D and calcium. Deflazacort treatment started between 4 and 8 years of age. Thirty-two were treated with protocol-T using deflazacort at a dose of 0.9 mg/kg per day plus daily vitamin D and calcium. Treatment started between 6 and 8 years of age. All boys were monitored every 4 to 6 months. The results were compared with age-matched control subjects in the two groups (19 for protocol-N and 30 for protocol-T). For the boys treated with protocol-N, the authors observed that 97% were ambulatory at 9 years (control, 22%), 35% at 12 years (control, 0%), and 25% at 15 years (control, 0%). For the 32 boys treated with protocol-T, the authors reported that 100% were ambulatory at 9 years (control, 48%), 83% at 12 years (control, 0%), and 77% at 15 years (control, 0%). In boys aged 13 and older, a scoliosis of greater than 20°d eveloped in 30% of the boys on protocol-N, 16% on protocol-T, and 90% of control subjects. For protocol-N, no cataracts were observed, whereas in protocol-T, 30% of boys had asymptomatic cataracts that required no treatment. Fractures occurred in 19% (control, 16%) of boys in protocol-N and 16% (control, 20%) of boys on protocol-T. The authors conclude that: 1) collaborative studies are important to develop treatment protocols in DMD; 2) deflazacort treatment long term has beneficial effects in both protocols; 3) the protocol-T seems to be more effective and frequently is associated with asymptomatic cataracts; and 4) alternate-day administration seems less effective than daily treatment and the long-term beneficial effects of steroid treatment in both protocols have a dosedependent response for deflazacort. Biggar et al 28 designed a study to report deflazacort long-term effects on muscle strength and side effects in DMD. The study involved 54 boys (30 treated with deflazacort), aged between 7 and 15 years with DMD, who were reviewed retrospectively. The authors observed that: 1) the boys not treated with deflazacort stopped walking at 9.8 6 1.8 years; 2) seven of 30 treated boys had stopped walking at 12.3 6 2.7 years (P < 0.05), and of the 23 boys who were still walking, 21 were older than 10 years; 3) pulmonary function (percent predicted functional vital capacity) was significantly greater in treated boys at 15 years (88% 6 18%) than in boys not treated (39% 6 20%) (P < 0.001); 4) between 9 and 15 years, treated boys were shorter; 5) between 9 and 13 years, treated boys weighed less; 6) after 13 years, the treated boys maintained their weight, whereas boys not treated lost weight; 7) asymptomatic cataracts developed in 10 of 30 boys who received deflazacort; and 8) hypertension, glucosuria, acne, infection, and bruising were not more common. The authors conclude that deflazacort can preserve gross motor and pulmonary function in boys with DMD with limited side effects. Deflazacort, as this study shows, seems to have a very significant impact on health, quality of life, and healthcare costs for boys with DMD and their families and it is associated with few side effects, but it must be considered only a starting point for a future and more complete solution. 30 collected data over an 8-year period for 79 patients with DMD, 37 of whom were treated with deflazacort. Deflazacort (dose of 0.9 mg/kg adjusted to a maximum of 1 mg/kg according to the side effects) was started when boys showed functional decline resulting in difficulties to ambulate. The mean length of treatment was 66 months. Treated boys stopped walking at 11.5 6 1.9 years, whereas nontreated boys stopped walking at 9.6 6 1.4 years. Cardiac function, assessed by echocardiography every 6 to 12 months, was better preserved as shown by a normal shortening fraction in treated (30.8% 6 4.5%) versus untreated boys (26.6% 6 5.7%, P < 0.05), a higher ejection fraction (52.9% 6 6.3% treated versus 46% 6 10% untreated), and lower frequency of dilated cardiomyopathy (32% treated versus 58% untreated). No change was observed in blood pressure, left ventricle end-diastolic diameter, or cardiac mass. Scoliosis was much less severe in treated (14°6 22.5°) than in untreated boys (46°6 224°) and no spinal surgery was necessary in treated boys. Limb fractures occurred in 24% of treated and in 26% of untreated boys, whereas vertebral fractures occurred only in the treated group (seven of 37 compared with zero for the untreated group). In both groups, weight excess was observed at 8 years of age, and its frequency tripled between the ages of 8 and 12 years. More patients had weight excess in the treated group (13 of 21 [62%]) than in the untreated group (six of 11 [55%]) at 12 years of age. Cataracts developed in 49% of the treated patients and in almost all of these patients developed after at least 5 years of treatment. The authors confirmed that deflazacort use in DMD prolongs walking by at least 2 years, slows the decline of vital capacity, and postpones the need for mechanical ventilation.
Quality of life seemed improved in terms of prolonged independence in transfers and rolling over in bed as well as sitting comfortably without having to resort to surgery.
Manzur et al 31 realized a study to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD. The authors collected all the randomized or quasirandomized trials involving patients with a definite diagnosis of DMD who were treated with glucocorticoids such as prednisone, prednisolone, deflazacort, or others with a minimum treatment period of 3 months. The primary observed outcome measure was the prolongation of walking (independent walking without long leg calipers). The secondary observed outcome measures were strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures, and adverse events. The authors identified six randomized controlled trials that met the inclusion criteria. The data from one small study used prolongation of walking as an outcome measure and did not show significant benefit. The meta-analysis of the results from four randomized controlled trials with 249 participants showed that glucocorticoid corticosteroids improved muscle strength and function over 6 months. Improvements were seen in time taken to rise from the floor (Gowers' time), 9 m walking time, four-stair climbing time, ability to lift weights, leg function grade, and forced vital capacity.
One randomized controlled trial with 28 participants showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to 2 years. The most effective
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prednisolone regime appears to be 0.75 mg/kg per day given in a daily dose regime. Not enough data were available to compare efficacy of prednisone with deflazacort. The following adverse effects had been seen: excessive weight gain, behavioral abnormalities, cushingoid appearance, and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long-term adverse effects of glucocorticoid therapy could not be evaluated because of the short-term duration of the randomized studies. A number of nonrandomized studies with important efficacy and adverse effects data were tabulated and discussed. The authors concluded that there is evidence from randomized controlled studies that glucocorticoid corticosteroid therapy in DMD improves muscle strength and function in the short term (6 months to 2 years); the most effective prednisolone regime appears to be 0.75 mg/kg per day given daily; in the short term, adverse effects were significantly more common but not clinically severe; long-term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomized studies; nonrandomized studies support the conclusions of functional benefits, but also identify clinically significant adverse effects of long-term treatment; these benefits and adverse effects have implications for future research studies and clinical practice. Balaban et al 32 realized a study to determine and compare the long-term effects of prednisone and deflazacort on 49 boys aged 12 to 15 years with DMD over a 7-year followup period. Eighteen had been treated with prednisone, 12 with deflazacort, and 19 had no drug treatment. Analyzing lower and upper limb motor functions, pulmonary function, prevalence of surgery for scoliosis, and side effects, they reach these results: boys in the steroid groups were significantly more functional and performed better on all tests than boys not treated (P < 0.05); there was no significant difference between the deflazacort-and prednisone-treated groups (P > 0.05); the number of boys having scoliosis surgery among the treated groups was significantly less than nontreated boys (P < 0.05); the control group's pulmonary capacity was decreasing and significantly less than both prednisone-and deflazacort-treated boys; both deflazacort and prednisone had beneficial effects on pulmonary function and scoliosis; cataracts, hypertension, behavioral changes, excessive weight gain, and vertebral fracture were noted as serious side effects.
The results of this long-term study are very encouraging and both prednisone and deflazacort seem to have a significant beneficial effect on slowing the disease progress. Their use in DMD may prolong ambulation and upper limb function with similar potency. Both steroids are also able to improve pulmonary function, in addition to delay the need for spinal interventions, with similar therapeutic profiles. Dubowitz et al 33 reported a 5-year follow up of two 4-year-old boys with classic Duchenne dystrophy with an out-of-frame deletion in the Duchenne gene and absence of dystrophin in their muscle, who had a quite remarkable response to an intermittent, lowdosage regime of prednisolone (0.75 mg/kg per day for 10 days each month or alternating 10 days on and 10 days off). The authors reported that: 1) in the first case, there was complete remission of all clinical signs of dystrophy, sustained almost fully up to the present time; and 2) in the second, the initial response was almost as marked, sustained for almost 5 years before showing a fairly rapid decline over the ensuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th percentile for height and weight and showed no evidence of demineralization of bone on consecutive dual x-ray absorptiometry scanning of the spine nor any signs of chronic prednisolone toxicity. Although this study involved a limited number of patients, it showed that there may be an optimal window for treatment in the early stages of the disease and further larger-scale controlled studies should be targeted more selectively at this stage of the disease. This report also showed treatment, with either prednisone or deflazacort, appears to have an impact on the decline in cardiac function seen with DMD and are equally effective at preserving cardiac function. Shortening fraction was significantly lower in the untreated group than in the steroid-treated group. Despite the theoretical adverse effects of steroid use to cardiac function such as obesity, ventricular hypertrophy, hypertension, and lipid abnormalities, the benefits appear to outweigh these risks. The beneficial impact of steroid treatment on cardiac function may be sustained beyond the duration of treatment prolonging survival in patients with this disease. Griggs et al 35 reports a randomized controlled trial of prednisone and azathioprine with the aim to assess the longer-term effects of prednisone and to determine whether azathioprine alone or in combination with prednisone is able to improve strength. The study involved 99 boys aged 5 to 15 years affected by DMD. They were divided into three groups: placebo; 0.3 mg/kg prednisone per day; and 0.75 mg/kg prednisone per day. After 6 months, 2 to 2.5 mg/kg azathioprine per day was added into the first two groups and placebo added to the third group. The study showed that the beneficial effect of prednisone (0.75 mg/kg per day) is maintained for at least 18 months and is associated with a 36% increase in muscle mass. Weight gain, growth retardation, and other side effects were associated with prednisone and azathioprine did not have a beneficial effect. The authors concluded that prednisone's beneficial effect is not the result of immunosuppression.
Markham et al 36 studied the effect of steroids in cardiac function of patients with DMD. They evaluated left ventricular systolic function and cardiac geometry of those subjects through transthoracic echocardiogram; 111 patients 21 years of age or younger affected by DMD were selected. They were divided into two groups: untreated (never exposed or treated for less than 6 months) and steroid-treated (steroids were administered longer than 6 months); subjects did not differ in age, height, weight, body mass index, systolic and diastolic blood pressure, or left ventricular mass. Among the treated patients, 29 received prednisone and 19 received deflazacort. There was no difference in the shortening fraction between the two treated subgroups. Treated subjects not receiving steroids still had a normal shortening fraction, which was no different from the shortening fraction of those still receiving treatment. The authors concluded that in DMD, cardiac function, as measured by shortening fraction, remains normal until approximately the age of 10 years in the majority of patients. Kirschner et al 37 conducted a randomized, multicenter, double-blind placebo-controlled trial. One hundred fifty-three patients were randomized to receive either placebo or 4 mg/kg CsA. After 3 months, both groups received additional treatment with intermittent prednisone (0.75 mg/kg, 10 days on/10 days off) for another 12 months. In each group, 73 patients were available for intention-to-treat analysis. Baseline characteristics were comparable in both groups. There was no significant difference between the two groups concerning primary (manual muscle strength according to Medical Research Council) and secondary (myometry, loss of ambulation, side effects) outcome measures. Peak CsA values were measured blindly and ranged from 12 to 658 ng/mL (mean, 210 ng/mL) in the verum group. The authors concluded that CsA does not improve muscle strength as a monotherapy and does not improve the efficacy of intermittent prednisone in DMD. Calcineurin inhibitors induced chronic nephrotoxicity as described by Naesens et al. 38 They observed that calcineurin inhibitors after renal and nonrenal transplantation alter all kidney compartments (glomeruli, arterioles, tubule interstitium 35 DMD patients' data who were treated with 0.75 mg/kg prednisone per day intermittently 10 days on/10 days off. Prednisone was started during the ambulant phase at age 3.5 to 9.7 years (median, 6.5 years). The median period of treatment was 27 months (range, 3-123 months). The authors reported the following results: the median age at which ambulation was lost was 10.8 years (mean, 10.9 years; 95% confidence interval, 10.0-11.8 years); nine patients (26%) had excessive weight gain; eight boys (21%) had a bone fracture, which was when four of these eight children lost the ability to walk. The treatment was stopped in two obese patients, two hyperactive boys, and one patient after a fracture. Based on the previously described data, the authors conclude that prednisone 10 days on/10 days off has relatively few side effects and extends the ambulant phase by 1 year compared with historical controls.
OXANDROLONE IN CLINICAL TRIALS
Oxandrolone (Fig. 11) is an anabolic steroid and corresponds to the chemical name of the active ingredient in oxandrin and ANAVAR. Oxandrin is a registered trademark of (BioTechnology General Corp.; NASDAQ:BTGC) in the United States and/or other countries. ANAVAR was originally the registered trademark of Searle Laboratories. This androgenic steroid with potential neuroprotective properties is widely used to prevent muscle loss and is not immunosuppressive. Oxandrolone increased locomotor recovery concomitant with reduced loss of cord tissue in a standard weight drop model of spinal cord contusion injury. 41 As DMD with oxandrolone for 3 months. They observed an improvement of 0.315 6 0.097 (mean of the changes in the average muscle score). The expected mean change in muscle score after 3 months from natural history data is a loss of 0.1. The difference of 0.415 between the actual and expected values is significant at P < 0.01. These data, although derived from a short-numbered study, suggest that oxandrolone treatment may provide functional benefit for DMD-affected children. Following the encouraging results from a preliminary study, Fenichel et al 44 realized in 1997 (reported in the previous paragraph) a 6-month, randomized, double-blind, placebocontrolled study of oxandrolone in boys with an established diagnosis of DMD performed in 2001. The authors used a change from baseline to 6 months in the average muscle strength score as the primary efficacy measure. The authors reported: 1) the mean change from baseline for the oxandrolone group was +0.035; and 2) the mean change from baseline for the placebo group was -0.140. Although the oxandrolone group did not get worse and the patients taking the placebo showed some deterioration in strength, the difference was not significant (P = 0.13). The average of the four quantitative muscle tests (QMTs) showed a significant improvement in the oxandrolone-treated boys as compared with placebo. No adverse reactions attributable to oxandrolone were recorded. Oxandrolone did not produce a significant change in the average manual muscle strength score as compared with placebo, but the mean change in QMT was significant. The authors concluded that oxandrolone may be useful before initiating corticosteroid therapy because it is safe, accelerates linear growth, and may have some beneficial effect in slowing the progress of weakness.
SUMMARY
The Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society 45 have developed practice parameters as strategies for the management of corticosteroid treatment in boys with DMD. The guideline authors reviewed all available research concluding that prednisone has a beneficial effect on muscle strength and function in boys with DMD and should be offered (at a dose of 0.75 mg/kg per day) as treatment. The side effects may require a decrease in prednisone to dosages of 0.3 mg/kg per day giving less robust but significant improvement. Deflazacort (0.9 mg/kg per day) can also be used for the treatment of DMD in countries where it is available. Benefits and side effects of corticosteroid therapy need to be monitored. The guideline authors emphasize that an offer of treatment with corticosteroids should include a balanced discussion on potential benefits and risks. Possible side effects of corticosteroid therapy should be closely monitored by a physician. A nutrition and exercise program may prevent some of these side effects. Unfortunately, great concern has risen about the multiple side effects of immunosuppression with possible infections and induction of lymphomas and cancers in the long run, and multi-, low-dosage, immunosuppressive compounds might be the right answer to counteract the risk of complications.
Ideally, the best choice should enclose a mix of drugs able to preserve the existing
Iannitti et al
Journal of muscle mass function, guaranteeing homologous graft survival, and integration in the contracting network.
In the future, as a result of the great toxicities, risks, and serious side effects associated with the use of immunosuppressant drugs, it could be important to consider also hematopoietic cell transplantation as a serious alternative for the treatment of DMD. In fact, Parker et al 46 The immunosuppressant drugs characteristics are summarized in Table 1 and  Table 2 .
CONCLUSIONS
These studies and clinical trials update the immunosuppressant drugs use in DMD. Summarizing, we reached the following conclusions. Debio 025 is able to improve the structure and the function of the dystrophic mouse muscle. Those findings are encouraging for the future use of immunosuppressant drugs in the treatment of DMD. CsA is able to improve many functional, histologic, and biochemical end points associated with DMD and in the future it may contribute to a better graft survival in clinical transplantation. Calcineurin increases the expression of the markers of regeneration, in particular developmental myosin heavy chain isoform and myocyte enhancer factor 2A, and is able to significantly improve the mdx pathophysiology through its effects on muscle degeneration and regeneration and endurance capacity; etanercept use evidences a reduced breakdown of mdx skeletal muscle leading to a potential application to muscular dystrophies in the near future. Infliximab seems to greatly reduce the breakdown of dystrophic muscle and the necrosis and the dystropathology without adverse effect on new muscle formation. Deflazacort, but not prednisone, promotes myogenic repair over short and longer terms and is able to stimulate fiber growth. Some studies evidence that both seem to have a significant beneficial effect on slowing DMD progress. Their use may prolong ambulation and upper limb function. Both steroids are also able to improve pulmonary function in addition to delay the need for spinal interventions with similar therapeutic profiles. Deflazacort shows very important improvements in walking by at least 2 years, slows the decline of vital capacity, and postpones the need for mechanical ventilation in patients with DMD. Deflazacort has also got a very significant impact on health, quality of life (prolonged independence in transfers and rolling over in bed as well as sitting comfortably without having to resort to surgery), and healthcare costs for patients with DMD and their families, but it has to be considered only a start point to a future and more complete solution. MMF treatment inhibits muscle degeneration in mdx mice better than steroids. MMF shows improvements in necrosis and degeneration in the quadriceps and tibialis anteriors reducing the percentage of centrally located nuclei in the quadriceps and tibialis anterior muscles of mdx mice better than sterioids. MMF is already used safely in transplant patients and it could be one of the best candidates for DMD treatment. Lately, it has been hypothesized that treatment of mdx mice with inhibitors of the proteasomal pathway could potentially rescue the expression level and localization pattern of dystrophin and dystrophin-associated proteins. In fact, there is evidence that the loss of dystrophin in muscle cells derived from both mdx mice and DMD patients may render the dystrophin-glycoprotein complex (DGC) more susceptible to proteolytic degradation 47 and that the proteasomal pathway is involved in the pathogenesis of various muscle diseases. 48, 49 An experimental study 50 shows that in vivo administration of MG-132, an inhibitor of the proteasomal pathway, effectively restores the expression levels and the localization pattern of dystrophin and of dystrophin-associated proteins, normally absent or greatly reduced in mdx mice skeletal muscles. These findings have been later confirmed by the same research group 51 showing that treatment with MG-132 is able to rescue the expression of dystrophin, b-dystroglycan, and a-sarcoglycan in skeletal muscle explants from patients with Duchenne or Becker muscular dystrophy. The important results obtained from mdx mice and from DMD patients led this research group to test 2 new dipeptide boronic acid inhibitors blocking the proteasomal-dependent degradation pathway, that is, Velcade (bortezomib or PS-341; Food and Drug Administration approved for treatment of multiple myeloma) and MLN273 (PS-273). They injected Velcade and MLN273 into the mdx mice gastrocnemius muscle, observing the rescue of the expression of adystroglycan, b-dystroglycan, a-sarcoglycan, and dystrophin. Moreover, localized treatment with Velcade and MLN273 reduced the activation of nuclear factor-kappaB (NFkB), which is involved in a pathway linked to inflammation responses in myopathies and DMD. 52 A recent study 53 has shown that Velcade, a drug that selectively blocks the ubiquitin-proteasome pathway, when systemically administered in mdx mice over a 2-week period, restores the membrane expression of dystrophin and DGC members and improves the dystrophic phenotype. Moreover, the same study has shown that treating with the same compound explants from muscle biopsies of DMD or BMD patients, dystrophin, a-sarcoglycan, and b-dystroglycan protein levels are upregulated in explants from BMD patients, whereas the proteins of the dystrophin glycoprotein complex, in DMD cases, have increased. The ubiquitin-proteasome pathway blocker Velcade may have, in the future, important clinical implications for the pharmacological treatment of muscular dystrophy in humans, although further studies are required.
